Video: Dianthus for identifying Microcycle® hits

Transcription factors’ intrinsic disorder and lack of small molecule binding pockets make them difficult to drug, but one modality that has shown potential to target them is cyclic peptides.

In this talk, Dr. Gardner will explore how Curve Therapeutics integrated the Dianthus instrument with Spectral Shift technology into their screening cascade to validate cyclic peptide hits. He’ll present results with a focus on assay development, affinity screening, and data processing.